vs
Cue Biopharma, Inc.（CUE）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
RBB Bancorp的季度营收约是Cue Biopharma, Inc.的1.5倍（$32.3M vs $21.9M），RBB Bancorp净利率更高（31.5% vs 7.2%，领先24.3%），Cue Biopharma, Inc.同比增速更快（1292.3% vs 12.6%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs 7.0%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
CUE vs RBB — 直观对比
营收规模更大
RBB
是对方的1.5倍
$21.9M
营收增速更快
CUE
高出1279.7%
12.6%
净利率更高
RBB
高出24.3%
7.2%
两年增速更快
CUE
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $32.3M |
| 净利润 | $1.6M | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | 9.0% | 39.5% |
| 净利率 | 7.2% | 31.5% |
| 营收同比 | 1292.3% | 12.6% |
| 净利润同比 | 116.7% | 132.1% |
| 每股收益（稀释后） | $0.05 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERBB
| Q4 25 | $21.9M | $32.3M | ||
| Q3 25 | $2.1M | $32.6M | ||
| Q2 25 | $3.0M | $35.8M | ||
| Q1 25 | $421.0K | $28.5M | ||
| Q4 24 | $1.6M | $28.7M | ||
| Q3 24 | $3.3M | $30.3M | ||
| Q2 24 | $2.7M | $27.5M | ||
| Q1 24 | $1.7M | $28.2M |
净利润CUERBB
| Q4 25 | $1.6M | $10.2M | ||
| Q3 25 | $-7.4M | $10.1M | ||
| Q2 25 | $-8.5M | $9.3M | ||
| Q1 25 | $-12.3M | $2.3M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $-8.7M | $7.0M | ||
| Q2 24 | $-10.2M | $7.2M | ||
| Q1 24 | $-12.3M | $8.0M |
营业利润率CUERBB
| Q4 25 | 9.0% | 39.5% | ||
| Q3 25 | -353.4% | 40.7% | ||
| Q2 25 | -292.3% | 36.1% | ||
| Q1 25 | -2921.4% | 11.2% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | -264.2% | 31.6% | ||
| Q2 24 | -390.6% | 35.6% | ||
| Q1 24 | -737.8% | 39.9% |
净利率CUERBB
| Q4 25 | 7.2% | 31.5% | ||
| Q3 25 | -346.6% | 31.2% | ||
| Q2 25 | -287.1% | 26.1% | ||
| Q1 25 | -2911.4% | 8.0% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | -259.6% | 23.1% | ||
| Q2 24 | -382.7% | 26.4% | ||
| Q1 24 | -719.1% | 28.4% |
每股收益（稀释后）CUERBB
| Q4 25 | $0.05 | $0.59 | ||
| Q3 25 | $-0.07 | $0.59 | ||
| Q2 25 | $-0.09 | $0.52 | ||
| Q1 25 | $-0.17 | $0.13 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | $-0.17 | $0.39 | ||
| Q2 24 | $-0.20 | $0.39 | ||
| Q1 24 | $-0.25 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $26.4M | $523.4M |
| 总资产 | $42.2M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资CUERBB
| Q4 25 | $27.1M | $212.3M | ||
| Q3 25 | $11.7M | $234.9M | ||
| Q2 25 | $27.5M | $191.9M | ||
| Q1 25 | $13.1M | $238.8M | ||
| Q4 24 | $22.5M | $257.7M | ||
| Q3 24 | $32.4M | $349.4M | ||
| Q2 24 | $30.0M | $252.8M | ||
| Q1 24 | $41.0M | — |
总债务CUERBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | $1.0M | $119.4M | ||
| Q2 24 | $2.0M | $119.3M | ||
| Q1 24 | $3.0M | $119.2M |
股东权益CUERBB
| Q4 25 | $26.4M | $523.4M | ||
| Q3 25 | $13.2M | $514.3M | ||
| Q2 25 | $18.2M | $517.7M | ||
| Q1 25 | $6.6M | $510.3M | ||
| Q4 24 | $17.5M | $507.9M | ||
| Q3 24 | $25.4M | $509.7M | ||
| Q2 24 | $21.6M | $511.3M | ||
| Q1 24 | $30.0M | $514.0M |
总资产CUERBB
| Q4 25 | $42.2M | $4.2B | ||
| Q3 25 | $31.6M | $4.2B | ||
| Q2 25 | $40.7M | $4.1B | ||
| Q1 25 | $22.3M | $4.0B | ||
| Q4 24 | $32.2M | $4.0B | ||
| Q3 24 | $44.8M | $4.0B | ||
| Q2 24 | $42.3M | $3.9B | ||
| Q1 24 | $54.0M | $3.9B |
负债/权益比CUERBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | 0.04× | 0.23× | ||
| Q2 24 | 0.09× | 0.23× | ||
| Q1 24 | 0.10× | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | — | $42.6M |
| 自由现金流率自由现金流/营收 | — | 131.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.5% |
| 现金转化率经营现金流/净利润 | -0.68× | 4.26× |
| 过去12个月自由现金流最近4个季度 | — | $73.5M |
8季度趋势，按日历期对齐
经营现金流CUERBB
| Q4 25 | $-1.1M | $43.4M | ||
| Q3 25 | $-9.0M | $2.1M | ||
| Q2 25 | $-3.4M | $21.7M | ||
| Q1 25 | $-8.2M | $7.8M | ||
| Q4 24 | $-36.3M | $58.5M | ||
| Q3 24 | $-7.5M | $24.5M | ||
| Q2 24 | $-10.0M | $11.7M | ||
| Q1 24 | $-9.8M | $4.8M |
自由现金流CUERBB
| Q4 25 | — | $42.6M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-3.4M | $21.6M | ||
| Q1 25 | $-8.3M | $7.6M | ||
| Q4 24 | $-36.4M | $57.7M | ||
| Q3 24 | $-7.5M | $24.2M | ||
| Q2 24 | $-10.0M | $11.5M | ||
| Q1 24 | $-9.8M | $4.7M |
自由现金流率CUERBB
| Q4 25 | — | 131.8% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | -116.5% | 60.2% | ||
| Q1 25 | -1976.7% | 26.7% | ||
| Q4 24 | -2309.3% | 201.0% | ||
| Q3 24 | -225.7% | 80.0% | ||
| Q2 24 | -376.2% | 42.0% | ||
| Q1 24 | -573.0% | 16.6% |
资本支出强度CUERBB
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.9% | 0.3% | ||
| Q1 25 | 35.6% | 0.6% | ||
| Q4 24 | 4.2% | 2.7% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 3.2% | 0.5% |
现金转化率CUERBB
| Q4 25 | -0.68× | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RBB
暂无分部数据
